Patient basic information Patient: Ms. Brenda Smith) Country: Ethiopia Diagnosis: Brain tumor Diagnostic Hospital: University of Hong Kong Shenzhen Hospital Treatment program: Immunotherapy + Targeted Treatment Accommodation number: 135 days Treatment cost: approximately 127,372 yuan Treatment effect: Stability of the condition After arriving at the Shenzhen Hospital of the University of Hong Kong, the International Medical Services team arranged for the first time multidisciplinary MDT for patients, developed individualized clinical pathways based on the patient's examination reports and physical condition, and provided full translation, accompaniment and landing services. During the treatment process, the team of experts at the Shenzhen Hospital of the University of Hong Kong used a comprehensive set of immunotherapies + targeted therapies.
During the treatment, the medical team closely monitored the patient's indicators, dynamic adjustment programs. After 135 days of systemic treatment and rehabilitation management, the patient's condition gradually improved, and various test indicators returned to normal areas, successfully reaching outpatient standards. Treatment results The patient's final condition stabilized.
When he left the hospital, the medical team developed a detailed return follow-up and rehabilitation plan for him, and continued to track recovery through a remote follow-up system. The patient commented: 'The level of expertise of Chinese doctors and the condition of equipment in Chinese hospitals impressed us, and every link from the ground to the hospital was well arranged. Thank you to the medical team at Shenzhen University Hospital in Hong Kong, and thank you for the attentive care of the translators and attendants.
'Mrs. Brenda has been criticized by experts as a typical case of cross-border suspected seriousness clinical cases. The University of Hong Kong Shenzhen Hospital relies on a multidisciplinary collaborative mechanism to develop an immunotherapy + targeted treatment program for brain tumors, reflecting the comprehensive strength of Chinese hospitals in the field of suspected disease diagnosis and a summary of how international medical services are regulated.